移至主內容

Surgery versus endoscopic therapies for early oesophageal cancer in Barrett's oesophagus

This Cochrane review has indicated that there are no randomised controlled trials to compare management options in this vital area, therefore trials should be undertaken as a matter of urgency. Current use of endotherapies in the care of patients with early cancer or high-grade dysplasia of Barrett's oesophagus should be at the recommendation of the multi-disciplinary team involved in individual care. Properly conducted randomised controlled trials comparing surgery with endotherapies should be conducted before any conclusions can be drawn.

背景

Barrett's oesophagus is one of the most common pre-malignant lesions in the world. Currently the mainstay of therapy is surgical management of advanced cancer but this has improved the five-year survival very little since the 1980s. As a consequence, improved survival relies on early detection through endoscopic surveillance programmes. Success of this strategy relies on the fact that late-stage pre-malignant lesions or very early cancers can be cured by intervention. Currently there is considerable controversy over which method is best: that is conventional open surgery or endotherapy (techniques involving endoscopy).

目的

We used data from randomised controlled trials (RCTs) to examine the effectiveness of endotherapies compared with surgery in people with Barrett's oesophagus, those with early neoplasias (defined as high-grade dysplasia (HGD) and those with early cancer (defined as carcinoma in-situ, superficially invasive, early cancer or superficial cancer T-1m (T1-a) and T-1sm (T1-b)).

搜尋策略

We used the Cochrane highly sensitive search strategy to identify RCTs in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), ISI Web of Science, EBMR, Controlled Trials mRCT and ISRCTN, and LILACS, in July and August 2008. The searches were updated in 2009 and again in April 2012.

選擇標準

Types of studies: RCTs comparing endotherapies with surgery in the treatment of high-grade dysplasia or early cancer. All cellular types of cancer were included (i.e. adenocarcinomas, squamous cell carcinomas and more unusual types) but will be discussed separately.

Types of participants: patients of any age and either gender with a histologically confirmed diagnosis of early neoplasia (HGD and early cancer) in Barrett's or squamous lined oesophagus.

Types of interventions; endotherapies (the intervention) compared with surgery (the control), all with curative intent.

資料收集與分析

Reports of studies that meet the inclusion criteria for this review would have been analysed using the methods detailed in Appendix 9.

主要結果

We did not identify any studies that met the inclusion criteria. In total we excluded 13 studies that were not RCTs but that compared surgery and endotherapies.

作者結論

This Cochrane review has indicated that there are no RCTs to compare management options in this vital area, therefore trials should be undertaken as a matter of urgency. The problems with such randomised methods are standardising surgery and endotherapies in all sites, standardising histopathology in all centres, assessing which patients are fit or unfit for surgery and making sure there are relevant outcomes for the study (i.e. long-term survival (over five or more years)) and no progression of HGD.

引用文獻
Bennett C, Green S, DeCaestecker J, Almond M, Barr H, Bhandari P, Ragunath K, Singh R, Jankowski J. Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus. Cochrane Database of Systematic Reviews 2020, Issue 5. Art. No.: CD007334. DOI: 10.1002/14651858.CD007334.pub5.

我們對Cookie的使用

我們使用必要的 cookie 使我們的網站正常運作。我們還希望設置可選擇分析的 cookie,以幫助我們進行改進網站。除非您啟用它們,否則我們不會設置可選擇的 cookie。使用此工具將在您的設備上設置 cookie,以記住您的偏好。您隨時可以隨時通過點擊每個頁面下方的「Cookies 設置」連結來更改 Cookie 偏好。
有關我們使用 cookie 的更多詳細資訊,請參閱我們的 cookie 頁面

接受所有
配置